BPC-157 vs TB-500
This page has not yet been reviewed by a credentialed medical professional. It is educational and is not medical advice.
Short answer: Neither has meaningful human evidence. BPC-157 has more animal data on tendons and the gut; TB-500 borrows most of its credibility from research on a different molecule, full-length thymosin beta-4.
| BPC-157 Animal studies only | TB-500 Animal studies only | |
|---|---|---|
| What it is | 15-amino-acid fragment of a gastric protein | Synthetic fragment sold as a form of thymosin beta-4 |
| Evidence grade | Animal studies only | Animal studies only |
| Human data | Three small pilot reports (a 17-patient uncontrolled knee review, interstitial cystitis, a 2-person IV pilot) | None for TB-500 itself; small trials of full-length Tβ4 in eye and heart |
| Best-studied area | Tendon, ligament and gut healing in rats | Cornea, skin and heart injury models (full-length Tβ4) |
| US status | Not approved; compounding rules changing in 2026 | Not approved; compounding rules under review in 2026 |
| Canada | Not authorized | Not authorized |
| WADA | Prohibited (S0) | Prohibited |
Takeaway
If you see them recommended as a "stack", note that no study has tested the combination for healing outcomes in people. The only human report that included both was a tiny knee-pain chart review where a few patients received both peptides.
FAQ
Which is better, BPC-157 or TB-500?
There is no human head-to-head evidence to say. Both are supported mainly by animal and cell research.
Can you stack BPC-157 and TB-500?
Combinations have not been tested in controlled human studies, so effects and safety of stacking are unknown.